个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Yu Xianzhe[1,2] ; Zhai Xiaoqian[1] ; Wu Juan[3] ; Feng Qingbo[4] ; Hu Chenggong[5] ; Zhu Lingling[1,*1] ; Zhou Qinghua[1,*1] ;
机构： [1]Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China [2]Department of Gastrointestinal Surgery, Chengdu Second People’s Hospital, No. 10 Qinyun Nan Street, Chengdu, Sichuan Province, People’s Republic of China [3]Out-patient Department, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China [4]Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Affiliated Digestive Hospital of Zunyi Medical University, Zunyi, Guizhou Province, People’s Republic of China [5]Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China
出处：
DOI： 10.1016/j.bbadis.2023.166881
ISSN：

关键词： Gastric cancer PD-1/PD-L1 Immune checkpoint inhibitors Immunotherapy

摘要：
Gastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignancies and is increasingly used in other clinical oncology treatments. Particularly, therapeutic antibodies targeting the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have been effectively used in the clinical treatment of cancer. Monoclonal antibodies blocking the PD-1/PD-L1 pathway have been developed for cancer immunotherapy to enhance T cell function to restore the immune response and represent a breakthrough in the treatment of GC. This review provides an outline of the progress of PD-1/PD-L1 blockade therapy and its expression characteristics and clinical application in advanced GC.Copyright © 2023. Published by Elsevier B.V.

基金：
National Natural Science Foundation of China (No. 82202989); the China Postdoctoral Science Foundation (No. 2022M722279, China); the Sichuan Science and Technology Program (No. 2023YFS0163, China); Postdoctoral Research Project of West China Hospital, Sichuan University, Chengdu, China (No. 2021HXBH045); Fundamental Research Funds for the Central Universities (No. 2022SCU1206); and Sichuan University Postdoctoral Interdisciplinary Innovation Fund (awarded to LZ, China).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物物理
最新[2023]版：
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物物理
第一作者：
第一作者机构： [1]Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China [2]Department of Gastrointestinal Surgery, Chengdu Second People’s Hospital, No. 10 Qinyun Nan Street, Chengdu, Sichuan Province, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China [*1]Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Yu Xianzhe,Zhai Xiaoqian,Wu Juan,et al.Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy[J].Biochimica et biophysica acta. Molecular basis of disease.2023,1870(1):166881.doi:10.1016/j.bbadis.2023.166881.
APA：
Yu Xianzhe,Zhai Xiaoqian,Wu Juan,Feng Qingbo,Hu Chenggong...&Zhou Qinghua.(2023).Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.Biochimica et biophysica acta. Molecular basis of disease,1870,(1)
MLA：
Yu Xianzhe,et al."Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy".Biochimica et biophysica acta. Molecular basis of disease 1870..1(2023):166881

相关文献

[1]中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版） [2]Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/ PD-L1 therapy [3]Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy [4]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [5]PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [6]The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials [7]PD-1/PD-L1在肝细胞癌治疗中的研究进展 [8]PD-1/PD-L1抑制剂在妇科肿瘤的研究进展 [9]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [10]Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号